AU2022244356A1 - Methods and materials for treatment of neisseria gonorrhoeae infection - Google Patents

Methods and materials for treatment of neisseria gonorrhoeae infection Download PDF

Info

Publication number
AU2022244356A1
AU2022244356A1 AU2022244356A AU2022244356A AU2022244356A1 AU 2022244356 A1 AU2022244356 A1 AU 2022244356A1 AU 2022244356 A AU2022244356 A AU 2022244356A AU 2022244356 A AU2022244356 A AU 2022244356A AU 2022244356 A1 AU2022244356 A1 AU 2022244356A1
Authority
AU
Australia
Prior art keywords
infection
compound
group
alkyl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022244356A
Other languages
English (en)
Inventor
Padinjaremadhorn V. RAMACHANDRAN
Mohamed Seleem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2022244356A1 publication Critical patent/AU2022244356A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022244356A 2021-03-26 2022-03-23 Methods and materials for treatment of neisseria gonorrhoeae infection Pending AU2022244356A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166309P 2021-03-26 2021-03-26
US63/166,309 2021-03-26
PCT/US2022/021467 WO2022204231A2 (en) 2021-03-26 2022-03-23 Methods and materials for treatment of neisseria gonorrhoeae infection

Publications (1)

Publication Number Publication Date
AU2022244356A1 true AU2022244356A1 (en) 2023-09-28

Family

ID=83398108

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022244356A Pending AU2022244356A1 (en) 2021-03-26 2022-03-23 Methods and materials for treatment of neisseria gonorrhoeae infection

Country Status (8)

Country Link
US (1) US20250339401A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313040A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511945A (cg-RX-API-DMAC7.html)
KR (1) KR20230161962A (cg-RX-API-DMAC7.html)
CN (1) CN117396201A (cg-RX-API-DMAC7.html)
AU (1) AU2022244356A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211535A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022204231A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150719A1 (en) * 2022-02-03 2023-08-10 Purdue Research Foundation Alpha-methylene and aminomethyl lactones and lactams for treatment of clostridioides difficile infection (cdi)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500289A (ja) * 2001-06-13 2005-01-06 マグナケム インターナショナル ラボラトリーズ, インコーポレイテッド ラクトン処方物および使用方法
BRPI0620157A2 (pt) * 2005-12-15 2011-12-20 Activbiotics Pharma Llc usos de rifamicinas
US20210317099A1 (en) * 2020-04-09 2021-10-14 Purdue Research Foundation Safer, potent, and fast acting antimicrobial agents

Also Published As

Publication number Publication date
WO2022204231A3 (en) 2022-12-29
KR20230161962A (ko) 2023-11-28
CA3211535A1 (en) 2022-09-29
CN117396201A (zh) 2024-01-12
WO2022204231A2 (en) 2022-09-29
US20250339401A1 (en) 2025-11-06
EP4313040A2 (en) 2024-02-07
EP4313040A4 (en) 2025-02-12
JP2024511945A (ja) 2024-03-18

Similar Documents

Publication Publication Date Title
US11787801B2 (en) Protein kinase inhibitors, preparation method and medical use thereof
CA2736097C (en) Carbazole compounds for inhibition of nf-kb activity
JP2022043078A (ja) 抗菌化合物
JP2026004421A (ja) 抗体-薬物複合体に適した毒素分子
JP2007517861A (ja) カンナビノイドのキノン派生物の治療使用方法
US11986459B2 (en) Methods for the treatment of Mycobacterium infections
JP2025526425A (ja) 抗体薬物複合体に適した毒素分子
CA3023171A1 (en) Phenyl [a]indole[2,3-g]quinolizine compounds, preparation method therefor, pharmaceutical composition, and applications thereof
KR20240055751A (ko) Bcl-2 패밀리 단백질을 분해하는 화합물 및 이의 의약에서의 응용
EP4313040A2 (en) Methods and materials for treatment of neisseria gonorrhoeae infection
CA3238595A1 (en) 15-pgdh inhibitor and use thereof
EP3369740B1 (en) New cytidine derivative dimers and applications thereof
CN118406042B (zh) 含吡啶环的两亲性蛇床子素-季铵盐杂合体及其制备方法和抗菌应用
CN113248524A (zh) 一种双吲哚生物碱化合物及其合成方法和用途
EA034063B1 (ru) Антибактериальные средства на основе производных ципрофлоксацина
JP2002535276A (ja) 4−デメチルペンクロメジンのアシル誘導体、その使用及び調製
US20250195490A1 (en) Alpha-methylene and aminomethyl lactones and lactams for treatment of clostridioides difficile infection (cdi)
CN119661519B (zh) 一种具有光动力抗菌作用的新型咔啉季铵盐类化合物的制备方法与应用
EP1758904B1 (en) Flavopereirine derivatives for cancer therapy
CN116120327B (zh) β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用
CN103724271B (zh) 取代咪唑-1-乙烯类化合物及其用途
Baker et al. Methods for the treatment of Mycobacterium infections
RU2477127C1 (ru) Получение квартернизованных производных усниновой кислоты и их биологические свойства
JP2026506166A (ja) miR-124誘導剤及びその調製方法及び用途
WO2000055160A1 (fr) Composition pharmaceutique a base de composes polyaromatiques